Breast Neoplasms  >>  sagopilone (BAY86-5302)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sagopilone (BAY86-5302) / Bayer
NCT00288249 / 2005-003216-30: Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer

Completed
2
82
Europe
Sagopilone (BAY86-5302, ZK 219477)
Bayer
Breast Neoplasms, Breast Cancer, Metastatic
03/08
01/09
NCT00313248: Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

Completed
2
65
US, Canada
Sagopilone (ZK 219477), BAY86-5302
Bayer
Breast Neoplasm
10/08
11/08
NCT00496379: ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

Terminated
2
15
US
ZK219477, ZK-EPO, ZK-Epothilone, Sagopilone
Nancy Lin, MD, Brigham and Women's Hospital, Bayer, Breast Cancer Research Foundation
Breast Cancer, CNS Disease
10/09
01/12

Download Options